{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8"},{"groupId":"OG001","value":"92.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2292"},{"groupId":"OG001","value":"2310"}],"units":"Participants"}],"title":"Baseline: No problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2"},{"groupId":"OG001","value":"6.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2292"},{"groupId":"OG001","value":"2310"}],"units":"Participants"}],"title":"Baseline: Some problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2292"},{"groupId":"OG001","value":"2310"}],"units":"Participants"}],"title":"Baseline: Confined to bed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.5"},{"groupId":"OG001","value":"74.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2080"},{"groupId":"OG001","value":"2129"}],"units":"Participants"}],"title":"Week 13: No problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1"},{"groupId":"OG001","value":"24.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2080"},{"groupId":"OG001","value":"2129"}],"units":"Participants"}],"title":"Week 13: Some problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"},{"groupId":"OG001","value":"0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2080"},{"groupId":"OG001","value":"2129"}],"units":"Participants"}],"title":"Week 13: Confined to bed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.8"},{"groupId":"OG001","value":"82.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2062"},{"groupId":"OG001","value":"2081"}],"units":"Participants"}],"title":"Week 25: No problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1"},{"groupId":"OG001","value":"17.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2062"},{"groupId":"OG001","value":"2081"}],"units":"Participants"}],"title":"Week 25: Some problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1"},{"groupId":"OG001","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2062"},{"groupId":"OG001","value":"2081"}],"units":"Participants"}],"title":"Week 25: Confined to bed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.1"},{"groupId":"OG001","value":"84.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2051"},{"groupId":"OG001","value":"2106"}],"units":"Participants"}],"title":"EOT: No problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8"},{"groupId":"OG001","value":"14.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2051"},{"groupId":"OG001","value":"2106"}],"units":"Participants"}],"title":"EOT: Some problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1"},{"groupId":"OG001","value":"0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2051"},{"groupId":"OG001","value":"2106"}],"units":"Participants"}],"title":"EOT: Confined to bed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8"},{"groupId":"OG001","value":"87.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1920"},{"groupId":"OG001","value":"1919"}],"units":"Participants"}],"title":"FU Month 18: No problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2"},{"groupId":"OG001","value":"12.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1920"},{"groupId":"OG001","value":"1919"}],"units":"Participants"}],"title":"FU Month 18: Some problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1"},{"groupId":"OG001","value":"0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1920"},{"groupId":"OG001","value":"1919"}],"units":"Participants"}],"title":"FU Month 18: Confined to bed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.8"},{"groupId":"OG001","value":"87.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1864"},{"groupId":"OG001","value":"1877"}],"units":"Participants"}],"title":"FU Month 24: No problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1"},{"groupId":"OG001","value":"12.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1864"},{"groupId":"OG001","value":"1877"}],"units":"Participants"}],"title":"FU Month 24: Some problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1"},{"groupId":"OG001","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1864"},{"groupId":"OG001","value":"1877"}],"units":"Participants"}],"title":"FU Month 24: Confined to bed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.5"},{"groupId":"OG001","value":"87.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1822"},{"groupId":"OG001","value":"1795"}],"units":"Participants"}],"title":"FU Month 36: No problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5"},{"groupId":"OG001","value":"12.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1822"},{"groupId":"OG001","value":"1795"}],"units":"Participants"}],"title":"FU Month 36: Some problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1822"},{"groupId":"OG001","value":"1795"}],"units":"Participants"}],"title":"FU Month 36: Confined to bed"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2400"},{"groupId":"OG001","value":"2404"}],"units":"Participants"}],"description":"EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \\[scored as 1\\], some or moderate problems \\[scored as 2\\], and extreme problems \\[scored as 3\\]). Percentage of participants with each of the following responses in mobility domain was reported: I have no problems in walking about; I have some problems in walking about; and I am confined to bed. Response percentages may not add up to 100% due to data rounding.","groups":[{"description":"Participants received pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\\^2 + epirubicin 90-120 mg/m\\^2 or doxorubicin 50 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\\^2 for 3 cycles, 75 mg/m\\^2 in first cycle and 100 mg/m\\^2 in subsequent cycles, or 75 mg/m\\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\\^2 or epirubicin 90-120 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).","id":"OG000","title":"Pertuzumab + Trastuzumab + Chemotherapy"},{"description":"Participants received placebo matched to pertuzumab IV Q3W and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\\^2 + epirubicin 90-120 mg/m\\^2 or doxorubicin 50 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\\^2 for 3 cycles, 75 mg/m\\^2 in first cycle and 100 mg/m\\^2 in subsequent cycles, or 75 mg/m\\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\\^2 or epirubicin 90-120 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\\^2 + carboplatin AUC 6 (up to 900 mg).","id":"OG001","title":"Placebo + Trastuzumab + Chemotherapy"}],"paramType":"NUMBER","populationDescription":"ITT population. Number analyzed=participants evaluable for this outcome measure at specified timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36","title":"Percentage of Participants With Response for European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Mobility Domain","type":"SECONDARY","unitOfMeasure":"percentage of participants"}